出典: meddic


  • Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P, Wozniak A, Schoffski P, Marynen P, Debiec-Rychter M.
Clin Cancer Res. 2008 Sep 15;14(18):5749-58.
PMID 18794084

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression.
  • Sánchez-Martín D1, Otsuka A1, Kabashima K1, Ha T1, Wang D1, Qian X1, Lowy DR1, Tosato G1.
  • Journal of the National Cancer Institute.J Natl Cancer Inst.2017 Nov 30. doi: 10.1093/jnci/djx219. [Epub ahead of print]
  • PMID 29202196
  • Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
  • Nam S1,2, Kim H2, Hong D2, Park JB1,2,3, Kim SJ4,2,3.
  • Anticancer research.Anticancer Res.2017 Nov;37(11):6291-6302.
  • PMID 29061812
  • Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
  • Calero R1, Morchon E2, Martinez-Argudo I3, Serrano R4.
  • Cancer letters.Cancer Lett.2017 Oct 10;406:1-11. doi: 10.1016/j.canlet.2017.07.021. Epub 2017 Aug 1.
  • PMID 28774796
  • In vitro investigation of the effect of matrix molecules on the behavior of colon cancer cells under the effect of geldanamycin derivative.
  • Vural K1, Kosova F2, Kurt FÖ3, Tuğlu İ4.
  • Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.Tumour Biol.2017 Oct;39(10):1010428317720569. doi: 10.1177/1010428317720569.
  • PMID 29034805


  • HSP90阻害薬の幕開け : 非小細胞肺がんを中心に (抗がん剤治療の最前線 : 分子標的薬剤の使用による進歩(前篇)) -- (新たな標的となる遺伝子とその変異,新薬)


Overview. Retaspimycin hydrochloride (HCl), also known as IPI-504, is an intravenously administered, potent and selective heat shock protein 90 (Hsp90) inhibitor. Cancer cells depend on the Hsp90 chaperone to maintain many proteins ...
25 Feb 2010 ... Heat shock protein 90 (Hsp90) is an emerging cancer target. Function of Hsp90. • “Chaperone” protein necessary for stability and function of certain 'client' stability and function of certain client proteins. Function of Hsp90 in ...
2010年10月15日 ... Infinity Pharmaceuticals、 Inc. (NASDAQ: INFI) IPI-504 の段階 2 の調査、高度の非 小さいセル肺癌を持つ患者の小説によって IV 管理された Hsp90 シャぺロンの抑制剤 からの結果が、臨床腫瘍学 (NSCLC) (等 Sequist、 J Clin Oncol の ...


IPI 504, Retaspamycin, Retaspimycin « New IPI-504 retaspimycin HSP90 inhibitor IPI IPI-504 retaspimycin HSP90 inhibitor IPI IPI 504, Retaspamycin, Retaspimycin « New Combination of IPI-504 and docetaxel (DTX IPI 504, Retaspamycin, Retaspimycin « New  >> IPI-504 (Retaspimycin hydrochlorideIPI-504 (Retaspimycin HCl) | Hsp90




WordNet   license wordnet

「the 9th letter of the Roman alphabet」

PrepTutorEJDIC   license prepejdic


PrepTutorEJDIC   license prepejdic




PrepTutorEJDIC   license prepejdic

「(野球で)innings pitched」

"http://meddic.jp/IPI-504" より作成